Trial Profile
Phase III Randomized Study of Crenolanib Versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects With FLT3 Mutated Acute Myeloid Leukemia
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Crenolanib (Primary) ; Cytarabine; Daunorubicin; Midostaurin
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors AROG Pharmaceuticals
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 24 Aug 2018 Status changed from not yet recruiting to recruiting.
- 01 Jul 2018 Planned initiation date changed from 1 May 2018 to 1 Aug 2018.